MYB underexpression
|
Adenoid Cystic Carcinoma
|
MYB underexpression
|
Adenoid Cystic Carcinoma
|
tretinoin Sensitive: C3 – Early Trials
|
tretinoin Sensitive: C3 – Early Trials
|
NOTCH1 mutation
|
Adenoid Cystic Carcinoma
|
NOTCH1 mutation
|
Adenoid Cystic Carcinoma
|
tretinoin Sensitive: C3 – Early Trials
|
tretinoin Sensitive: C3 – Early Trials
|
NOTCH mutation
|
Adenoid Cystic Carcinoma
|
NOTCH mutation
|
Adenoid Cystic Carcinoma
|
AL101 Sensitive: C3 – Early Trials
|
AL101 Sensitive: C3 – Early Trials
|
NOTCH1 positive + FGFR2 mutation
|
Adenoid Cystic Carcinoma
|
NOTCH1 positive + FGFR2 mutation
|
Adenoid Cystic Carcinoma
|
lenvatinib + erdafitinib + γ-secretase inhibitor Sensitive: C4 – Case Studies
|
lenvatinib + erdafitinib + γ-secretase inhibitor Sensitive: C4 – Case Studies
|
MYB-NFIB fusion + BCOR F1106Tfs*5 + BCOR L1524Hfs*8
|
Adenoid Cystic Carcinoma
|
MYB-NFIB fusion + BCOR F1106Tfs*5 + BCOR L1524Hfs*8
|
Adenoid Cystic Carcinoma
|
anlotinib + eribulin mesylate Sensitive: C4 – Case Studies
|
anlotinib + eribulin mesylate Sensitive: C4 – Case Studies
|
BCOR L1524Hfs*8
|
Adenoid Cystic Carcinoma
|
BCOR L1524Hfs*8
|
Adenoid Cystic Carcinoma
|
anlotinib Sensitive: C4 – Case Studies
|
anlotinib Sensitive: C4 – Case Studies
|
BCOR F1106Tfs*5
|
Adenoid Cystic Carcinoma
|
BCOR F1106Tfs*5
|
Adenoid Cystic Carcinoma
|
anlotinib Sensitive: C4 – Case Studies
|
anlotinib Sensitive: C4 – Case Studies
|
MYB-NFIB fusion
|
Adenoid Cystic Carcinoma
|
MYB-NFIB fusion
|
Adenoid Cystic Carcinoma
|
M6620 Sensitive: D – Preclinical
|
M6620 Sensitive: D – Preclinical
|
PIK3CA mutation
|
Adenoid Cystic Carcinoma
|
PIK3CA mutation
|
Adenoid Cystic Carcinoma
|
PI3K inhibitor Sensitive: D – Preclinical
|
PI3K inhibitor Sensitive: D – Preclinical
|
MYB fusion + PIK3CA mutation
|
Adenoid Cystic Carcinoma
|
MYB fusion + PIK3CA mutation
|
Adenoid Cystic Carcinoma
|
PI3K inhibitor Sensitive: D – Preclinical
|
PI3K inhibitor Sensitive: D – Preclinical
|
AXL overexpression
|
Adenoid Cystic Carcinoma
|
AXL overexpression
|
Adenoid Cystic Carcinoma
|
ADCT-601 Sensitive: D – Preclinical
|
ADCT-601 Sensitive: D – Preclinical
|